BOLT · Insider Trading
Bolt Biotherapeutics, Inc. Common Stock
Every open-market purchase and sale reported by BOLT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-21 | Sarah Nemec | Senior VP, Finance and PAO | MIXED | −7,333 | −$24.10K |
| 2026-09-21 | Grant Yonehiro | Chief Operating Officer | Sell | −13,176 | −$43.81K |
| 2026-09-21 | William P. Quinn | President, CEO and CFO | MIXED | −16,929 | −$55.93K |
| 2026-06-11 | Nicole Onetto | Director | A | +5,000 deriv. | — |
| 2026-06-11 | Brian O'Callaghan | Director | A | +5,000 deriv. | — |
| 2026-06-11 | Laura Berner | Director | A | +5,000 deriv. | — |
| 2026-06-11 | Kathleen Laporte | Director | A | +5,000 deriv. | — |
| 2026-06-11 | Jakob Dupont | Director | A | +5,000 deriv. | — |
| 2026-02-04 | Grant Yonehiro | Chief Operating Officer | A | +10,000 deriv. | — |
| 2026-02-04 | Sarah Nemec | Senior VP, Finance and PAO | Buy | +125 | +$576 |
| 2026-02-04 | William P. Quinn | President, CEO and CFO | Buy | +125 | +$576 |
| 2025-12-16 | Laura Berner | Director | MIXED | — | — |
| 2025-12-16 | Nicole Onetto | Director | MIXED | — | — |
| 2025-12-16 | Kathleen Laporte | Director | MIXED | — | — |
| 2025-12-16 | Jakob Dupont | Director | MIXED | — | — |
| 2025-12-16 | Grant Yonehiro | Chief Operating Officer | MIXED | — | — |
| 2025-12-16 | William P. Quinn | President, CEO and CFO | MIXED | — | — |
| 2025-12-16 | Sarah Nemec | Senior VP, Finance and PAO | MIXED | — | — |
| 2025-12-16 | Brian O'Callaghan | Director | MIXED | — | — |
| 2025-10-24 | Sarah Nemec | Senior VP, Finance and PAO | MIXED | +23,125 | +$686 |
| 2025-10-24 | Grant Yonehiro | Chief Operating Officer | A | +30,000 | — |
| 2025-10-24 | William P. Quinn | President, CEO and CFO | MIXED | +40,125 | +$686 |
| 2025-07-02 | Laura Berner | Director | A | +1,100 deriv. | — |
| 2025-07-02 | Jakob Dupont | Director | A | +1,100 deriv. | — |
| 2025-07-02 | Kathleen Laporte | Director | A | +1,100 deriv. | — |
| 2025-07-02 | Brian O'Callaghan | Director | A | +1,100 deriv. | — |
| 2025-07-02 | Nicole Onetto | Director | A | +1,100 deriv. | — |
| 2025-05-05 | Jakob Dupont | Director | A | +20,000 deriv. | — |
| 2025-05-05 | Grant Yonehiro | Chief Operating Officer | A | +350,000 deriv. | — |
| 2025-05-05 | Sarah Nemec | Senior VP, Finance and PAO | Buy | +5,000 | +$2.83K |
| 2025-05-05 | William P. Quinn | President, CEO and CFO | Buy | +5,000 | +$2.83K |
| 2024-09-06 | Jakob Dupont | Director | A | +66,984 deriv. | — |
| 2024-07-24 | Grant Yonehiro | Chief Operating Officer | A | +155,000 deriv. | — |
| 2024-07-24 | William P. Quinn | President, CEO and CFO | A | +440,000 deriv. | — |
| 2024-07-24 | Sarah Nemec | VP, Finance and PAO | A | +140,000 deriv. | — |
| 2024-06-14 | Laura Berner | Director | A | +22,000 deriv. | — |
| 2024-06-14 | James Healy | Director | A | +22,000 deriv. | — |
| 2024-06-14 | Brian O'Callaghan | Director | A | +22,000 deriv. | — |
| 2024-06-14 | Kathleen Laporte | Director | A | +22,000 deriv. | — |
| 2024-06-14 | Nicole Onetto | Director | A | +22,000 deriv. | — |
| 2024-06-14 | Mahendra Shah | Director | A | +22,000 deriv. | — |
| 2024-06-14 | Frank D. Lee | Director | A | +22,000 deriv. | — |
| 2024-03-06 | Edith A. Perez | Chief Medical Officer | A | +235,000 deriv. | — |
| 2024-03-06 | Grant Yonehiro | Chief Business Officer | A | +235,000 deriv. | — |
| 2024-03-06 | William P. Quinn | Chief Financial Officer | A | +235,000 deriv. | — |
| 2024-03-06 | Randall C Schatzman | Chief Executive Officer | A | +654,000 deriv. | — |
| 2023-12-13 | William P. Quinn | Chief Financial Officer | Buy | +11,829 | +$11.24K |
| 2023-12-01 | Edgar Engleman | Director | Sell | −148,884 | −$128.99K |
| 2023-11-22 | Edgar Engleman | Director | Sell | −1,943 | −$1.75K |
| 2023-11-22 | Vivo Opportunity, LLC | 10%+ Owner | Sell | −23,800 | −$21.42K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| William P. Quinn | President, CEO and CFO | 41,061 | $270.59K |
| Grant Yonehiro | Chief Operating Officer | 24,119 | $158.94K |
| Sarah Nemec | Senior VP, Finance and PAO | 17,082 | $112.57K |
| Kathleen Laporte | Director | 60 | $395 |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BOLT quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.